

Can Too Foundation Annual Report

FY24/25



1

2	Overview
3	Highlights
6	A message from our Chair
9	A message from our CEO
10	Our impact
17	Our current funded researchers
19	Our community
22	Our partners
23	The Toucan Collective
24	Our Board Directors
25	Our team
27	Financial summary

2

Overview

Our vision

To transform lives - through improving health and wellbeing in the community and supporting the research, prevention, care and control of cancer.

Our values

Inspire - Engage - Support - Empower

Our dual mission

To inspire individuals to achieve personal health and wellbeing goals and to fund innovative early-career cancer research.

By combining physical fitness with a cause that matters, we empower ordinary people to make a significant impact in the fight against cancer.

About our Founder



Annie Crawford AM is the visionary founder of the Can Too Foundation.

Before founding CanToo in May 2005, Annie’s career was in social services and human resources. Drawing on her background in community-work and a deep personal motivation after losing her father to bowel cancer at 51, Annie set up CanToo as a small group of runners to run a marathon and raise funds to go directly to cancer research.

As a passionate runner and accredited running coach, she transformed her love of fitness into a philanthropic movement.

20 years on, CanToo has built an amazing and encouraging community who have raised over \$35 million to fund 161 research projects.

Highlights

3

1,047

Participants trained

\$900k

Funds raised by participants

16

Goal events

1,536

Hours of skilled volunteering

62

Pod groups trained

8

Cancer researchers supported

Since 2005:

\$35.8 million funds raised. 23,187 participants trained. 161 research projects supported. 143 researchers supported. 20 cancer types. 47 research leading institutes across Australia.



This funding has been essential in advancing my leadership role within translational childhood acute lymphocytic leukaemia research and nanomedicine, and positions the research program for future growth and larger competitive grants.

- Dr Narges Bayat




As an early-career researcher, CanToo funding supports my development towards becoming an independent researcher, allowing me to explore new ideas and make an impact in ovarian cancer research.

- Dr Laura Moffitt



Thank you to our partners and community for raising funds for critical research projects for our early-career cancer researchers, and to support and promote health and wellbeing within our pods. With your continued support we have raised over **\$35 million** over the past 20 years.



A message from our Chair



Barbara King
CanToo Chair

Dear CanToo community,

This year is a momentous one for Can Too Foundation, as it celebrates two incredible milestones: its **20th anniversary** and **\$35 million raised** for its dual mission of cancer research and health promotion, with over 161 cancer research projects funded for some of Australia's most brilliant young researchers. It also celebrates a very special community.

I encourage you to reflect on the impact CanToo has had for you; perhaps better mental and physical health rising to a run or ocean swim challenge, the joy of a new circle of friends, renewed hope in the discovery of a cure or more effective treatment for cancer.

On behalf of the Board, a heartfelt thank you for your part in this incredible journey.

This feels like a good time for a reset. The landscape for charities is very competitive. Like many, CanToo has had to be agile and adapt post-Covid, and significant work is going into refreshing its processes and strategy. I am optimistic about the way forward: we have dedicated Directors with support from new Advisors, an excellent, collaborative and hard-working team, committed Coaches and Leaders, and generous partners. The Board is ambitious to expand on CanToo's impact to transform lives and fund more research, although careful in setting course for the next 20 years to ensure that CanToo does the basics brilliantly.

And we should do that by putting people first and last, being true to Annie's original vision and CanToo's values. These are to **inspire, engage, support** and **empower**. The Board has asked that these values are embedded in everything that CanToo does and know our CEO has taken that to heart.

Delivering on CanToo's mission is a team effort and CanToo is fortunate to have a dedicated and expert team. In November, after a very competitive and rigorous process, the Board was delighted to welcome our new leader, CEO Lisa Hresc, who has hit the ground running in true CanToo spirit. We acknowledge and thank former CEO Paul Rose for his contribution in reshaping CanToo's strategy. It has been wonderful to see strong ties developing between Directors and staff, from an energising and engaging Director and staff strategy day in February, conducting cyber and program incident scenario testing together and even swimming the chilly Tasmanian waters with the new Hobart pod.

The continued collegiality of the Board, CEO and staff will be key to successfully implementing Lisa's excellent initiatives, including the new Toucan Collective for philanthropic giving, which grew out of the success of the CanToo Circle. Lisa's focus on people and culture, as well as participant experience, increasing funds to research and to cost control is strengthening CanToo's foundations.

Our CEO is ably supported by a hard-working and dedicated office team, professional Coaches and passionate volunteer Team Leaders and Mentors. Each is crucial to the participant experience and significant work is going into refreshing processes and communications to support them. I would also like to call out our private donors, major sponsor ASICS, our swimwear partner LAB, and key partners auditor Prosperity, pro bono law firm MinterEllison, and for 2025 Summer/Autumn swim, surf lifesaving clubs Elouera, Bondi, Manly, Mona Vale and Kingston (Hobart). Please know you are seen and greatly appreciated. Values alignment gives these relationships extra meaning.

A new panel of Advisors was established in November 2024 to support the Board and CEO with pro bono, ad hoc advice on specialist subject areas as needed. Thank you to Reyna Matthes, Alana Bowles, Kelly Bloore, Amber Conway and Marnie Edwards for sharing your expertise and passion for CanToo so generously.

Finally, sincere thanks to my fellow Board Directors, Ben Buckingham, Jeffrey Cohn, Antoine van Oijen, Mark Dagworthy and Dominic del Giudice for their generosity and wise counsel, particularly on the CEO recruitment and transition, and in giving their time freely. At the 2024 AGM, we said adieu to Directors Andrea Tustin, Sarv Girn and Anke Timm and thank them for their long-standing service and commitment. We are deeply grateful. We also farewell Jeffrey Cohn at the 2025 AGM, and note his proactive support particularly in driving the CanToo Circle, Business Supporters Network and leading the Research Committee; thank you, Jeffrey.

The Board's Audit & Risk and Research Committees do crucial work, respectively overseeing financial, safety and other risks and mitigation, and overseeing research funding and partnerships with Children's Cancer Institute and Hudson. These have been expertly chaired by Sarv Girn and Mark Dagworthy, and Jeffrey Cohn and Antoine van Oijen respectively, and the Board and committees have enjoyed the excellent support of Company Secretary, Gavin Le Roux and Board Observer, Emmy Fleuren.

I am confident with this strengthened network and governance structure, CanToo is well placed to deliver on its mission for years to come. After nine years working with the Board, first as Company Secretary, then as a Director, it is time for me to say a fond farewell and step down at the 2025 AGM to make way for fresh eyes and hands. I am deeply grateful for the trust Annie and Simon, and fellow Directors, placed in me, for the privilege of leading and getting to know such an incredible community who consistently show they can do difficult and brilliant things, for lifelong friendships formed, for personal growth and learning. I'm very proud of the community and the impact made together. Thank you to Annie in particular for sparking a movement that has been so transformative for me and so many, and for teaching the importance of values-based leadership.

I'm looking forward to seeing what CanToo's next chapter will bring: Go CanToo!

Barbara King

Board Chair



A message from our CEO

9



Lisa Hresc
CanToo CEO

This year has been one of remarkable commitment, resilience, and community spirit across the Can Too Foundation. As I reflect on the achievements of the past 12 months, I am reminded of what makes CanToo so special: a shared belief that everyday people can make an extraordinary difference in the world of cancer prevention and research.

Our community of participants, donors, Coaches, volunteers, partners, and researchers came together once again with a singular purpose - to support life-saving cancer research while empowering individuals to achieve personal health and fitness goals.

This year also marked CanToo's 20th Anniversary, we celebrate such an amazing achievement from Annie's vision to where the foundation is today. With our alumni of researchers with 161 research projects and over \$35 million raised by this community of over 23,000.

I extend my deepest gratitude to our community, our board, advisors, our researchers, our partners, everyone who contributed to our success. Your dedication ensures that CanToo remains a powerful force for good.

Thank you to our Board Chair, Barb, for her dedication to the cause, we wish her well on her next chapter. Grateful to Jeffrey Cohn, whose support and ongoing commitment to CanToo has been unmatched - we will miss you.

I personally would like to thank the CanToo team at HQ, our Coaches, Team Leaders and Mentors, and KG and Merick for showing me the way at each of our pods and at every event. And thank you to our participants who have allowed me to run and swim with them 🧡

Lisa Hresc
CEO

Our impact

10

Over the past 20 years, Can Too Foundation has funded over 140 early-career cancer researchers in Australia, thanks to our incredible participants and supporters. This support during the early phase of their careers enables them to develop track records and leadership skills, setting them up for long-term success in a highly competitive environment. Here we reflect on the journey and impact of three of these amazing researchers.

Professor Megan Hitchins

In 2006, Megan became CanToo's first funded early-career researcher, studying the causes of colorectal cancer. Today, she serves as a Principal Investigator in the Cancer Epidemiology Program at the Moffitt Cancer Center in Florida, the state's only National Cancer Institute-designated Comprehensive Cancer Center.

Megan's expertise in genetics, epigenetics, and translational medicine has established her as a leader in precision oncology. As an internationally recognised researcher, her contributions have reshaped our understanding of hereditary cancer risk, improved early detection, and benefited patients and families worldwide.

Megan's impact on hereditary and young-onset cancer

Megan has fundamentally reshaped our understanding and management of hereditary and young-onset cancers through her pioneering work in genetics, epigenetics, and biomarker development. Some of her most impactful research includes:

- **Discovery of epigenetic causes of Lynch syndrome:** Megan is internationally recognised for her pioneering work that demonstrated how epigenetic changes – specifically, DNA methylation – can lead to hereditary cancers associated with Lynch syndrome, a hereditary condition linked to an increased risk of colorectal and endometrial cancer. Prior to this, Lynch syndrome was solely connected to inherited mutations in DNA repair genes. However, Megan and her team discovered that a genetic change in the promoter region of the MLH1 gene resulted in methylation, which silenced this crucial anti-cancer gene. This finding clarified previously mysterious cases of inherited cancer risk and enabled the development of new genetic tests to identify at-risk families who would have otherwise remained undiagnosed.

- **Expanded screening guidelines for young-onset cancers:** Megan showed that MLH1 methylation is a characteristic of some young-onset colorectal and endometrial cancers. As standard sequencing methods did not detect methylation, many younger patients were not diagnosed promptly. Megan demonstrated that detecting MLH1 methylation in the blood of these young patients, rather than only in their tumours, has facilitated the integration of blood-based methylation testing into screening protocols for high-risk individuals.
- **Development of advanced blood-based early cancer detection tests:** Megan has led the development of minimally invasive, blood-based tests designed to detect colorectal cancer, focusing on younger patients (under 50) who are not eligible for traditional screening. Her team has identified a panel of circulating tumour DNA methylation markers that can sensitively detect both precancerous and cancerous changes. These findings support the utility of earlier and more accessible screening, as well as more rapid and inexpensive monitoring for cancer recurrence in patients who have undergone surgery.
- **Translational impact and clinical application:** Megan's research bridges molecular findings with clinical practice and has directly impacted patient care. By identifying the underlying genetic or epigenetic causes of cancer in patients and families where standard testing failed, Megan's research has influenced clinical guidelines and management, improved surveillance, and resulted in better outcomes for individuals with hereditary cancer syndromes.

Significance of early-career funding

The funding provided by Can Too Foundation in the early phase of Megan's research career supported her groundbreaking work on colorectal cancer methylation biomarkers and contributed to her evolution as a leader in translational epigenetics.

"I will always owe a debt of gratitude to the Can Too Foundation for trusting in me and supporting my research during the early phase of my career as I was emerging as an independent scientist. This award helped to leverage additional state and federal funding in Australia to expand the research, which was also a major step up in my career at that time.

Now, as a senior scientist and recipient and reviewer of USA National Cancer Institute grants, I am in the privileged position of being able to undertake and influence the direction of translational cancer research, whilst fostering the next generation of cancer researchers. The Can Too Foundation was a critical initiator in this."



Professor David Gallego Ortega

Funded by CanToo in 2012, David is now a leading cancer researcher and biomedical engineer. He serves as the Head of the School of Biomedical Engineering and the Director of the Single Cell Technology Facility at the University of Technology Sydney.

His career has been marked by groundbreaking work in breast cancer biology, particularly in developing personalised therapies and understanding treatment resistance.

David's impact in the field of breast cancer

Through pioneering innovations in personalised medicine and immunotherapy, David has advanced strategies for breast cancer treatment. Some of his most notable achievements include:

- **Development of the ALTEN device:** a groundbreaking technology that preserves tumour biopsies in a 3D environment, allowing for rapid and accurate testing of anticancer therapies. This approach enables clinicians to make real-time treatment decisions within weeks, bridging the gap between laboratory research and patient care, particularly for aggressive cancers such as triple-negative breast cancer.
- **Immunotherapy for triple-negative breast cancer:** His research on myeloid-derived suppressor cells (MDSCs) has revealed key mechanisms through which these cells suppress immune responses in breast cancer and promote tumour growth. By precisely targeting MDSCs with therapies that spare healthy immune cells, David and his team are establishing the groundwork for a new generation of immunotherapies that could improve outcomes for patients with aggressive breast cancer types. CanToo continues to support David and his team with this aspect of his research program.
- **Single-cell genomics expertise:** Under his leadership in single-cell genomics, David has offered unprecedented insights into cancer therapy. Understanding drug responses of individual cells within tumours paves the way for more personalised and effective cancer therapies, providing hope to patients around the globe.

Significance of early-career funding

Can Too Foundation's early-career funding in 2012 played a pivotal role in shaping David's career as a leading cancer researcher. The grant supported his investigation into anti-estrogen therapy resistance in breast cancer, allowing him to explore innovative ideas during a critical phase of his career.

"Early funding from CanToo was the cornerstone of my career. It ignited my creativity and empowered me to attract top government grants and forge international collaborations for ground-breaking research."

This initial support allowed Professor David Gallego Ortega to establish a strong track record, ultimately leading to his current roles as Head of the School of Biomedical Engineering and Director of the Single Cell Technology Facility at the University of Technology Sydney.

"Today, I am proud to mentor young, talented investigators whose dedication strives to improve patient outcomes. Just like me, they need that jump start in their careers to spark their innovation."

CanToo's investment not only jump-started David's career, but also contributed to advancements in cancer treatment strategies that continue to benefit patients worldwide.

"The work of CanToo and their critical support to young researchers not only boosts talent, but gives hope. It creates a legacy that is transforming cancer outcomes for generations to come. This journey is more than just scientific breakthroughs; it's about uniting everyone in the fight against a disease that touches us all."



Associate Professor Emmy Fleuren

Funded by CanToo in 2020 and 2021, Emmy has established the Sarcoma Biology and Therapeutics Group at Children's Cancer Institute in Sydney. This is Australia's first and only research group dedicated solely to sarcomas affecting young people. Sarcomas are a diverse group of cancers that affect the connective tissues of the body, primarily found in children, adolescents, and young adults.

Internationally recognised and driven by a commitment to precision medicine and kinder, more effective therapies, Emmy's research is shaping the future of sarcoma treatment and improving outcomes for young patients worldwide.

Emmy's impact in the field of sarcoma

Emmy has made significant contributions to improving the treatment of paediatric sarcoma through innovative approaches that focus on precision medicine and minimising treatment toxicity. Key achievements include:

- **Pioneering precision medicine for sarcoma:** Her work bridges laboratory discoveries to clinical practice by integrating multi-omics profiling and innovative phosphoproteomics to identify new, actionable targets for therapy. Through this approach, Emmy has increased the proportion of sarcoma patients receiving treatment recommendations.
- **Identifying novel therapeutic targets:** Emmy has identified and validated key proteins, such as FGFRs, as potential drivers in difficult-to-treat sarcomas. Her laboratory demonstrated that, in certain combinations, these inhibitors induce near-complete tumour regression in specific sarcoma subtypes, paving the way for clinical translation.
- **Reducing treatment toxicity:** Emmy's research aims to replace harsh chemotherapy regimens - unchanged for 40 years - with targeted drugs that protect healthy cells. She is leading research on kinase inhibitors and other drugs with fewer side effects than traditional therapies and has contributed to designing clinical trials in this area. Drugs with fewer side effects are important for the developing bodies of young patients.



- **Direct clinical impact:** Emmy's discoveries have been crucial in shaping clinical decision-making through the national ZERO Childhood Cancer Program, which she is involved in. She tests novel therapies in pre-clinical models and patient-derived cells, and integrates these novel findings with the patients' molecular profiles. This approach has already guided life-extending treatments for children with relapsed or metastatic sarcoma.



Significance of early-career funding

The initial support provided by Can Too Foundation during the early phase of Emmy's research career was transformative. The preliminary data and momentum generated through CanToo funding were pivotal in helping Emmy secure additional competitive research funding. It also enabled her to establish her own independent sarcoma research team and significantly advance the field of childhood cancer research.

"I really can't emphasise enough how critical support is at the start of your career. When you're early in your career it's very difficult to get the funds and set up your own research. CanToo funding allowed me to kick off my own independent career in cancer research, establish an independent research program, and expand my research team. I now lead my own sarcoma laboratory at the Children's Cancer Institute."

Emmy is also a CanToo-er, having participated in a CanToo ocean swim program. She is pictured above (right) with CanToo's Founder, Annie Crawford AM.

Our current funded researchers

17



Dr Sarah Boyle

Tackling breast cancer growth and metastasis by suppressing ROCK-regulated paracrine signalling.

Centre for Cancer Biology, University of South Australia



Dr Narges Bayat

Advancing leukaemia care: a new imaging tool for early detection and treatment monitoring.

Children's Cancer Institute, University of New South Wales



Dr Oliver Schumacher

Using exercise to improve radiotherapy effectiveness for prostate cancer.

Edith Cowan University



Dr Joshua Tobin

The role of lipids in immune response to follicular lymphoma.

Mater Research Institute, University of Queensland

18



Prof David Ziegler

Testing a new dual treatment for aggressive childhood brain cancers.

Children's Cancer Institute, University of New South Wales



Dr Laura Moffitt

Challenging cancer leader cells: the pioneers of cancer spread.

Hudson Institute of Medical Research



Prof David Gallego Ortega

Developing an immunotherapy for triple-negative breast cancer.

University of Technology Sydney



Dr Vasilios Panagopoulos

Targeted inhibition of myeloperoxidase: a new therapeutic strategy to prevent multiple myeloma disease progression.

South Australian Health and Medical Research Institute, University of Adelaide

Our community

19

Over the past 20 years, more than 23,000 individuals have participated in CanToo fitness programs. Supported by our expert Coaches, these participants have challenged themselves, pushed beyond their limits, and discovered their true potential, all while raising funds for innovative early-career cancer researchers.

Here we reflect on the journey of one of our inspiring participants and dedicated fundraisers.

Lizzie Crowhurst



Beginning with uncertainty

What began as a single program grew into a long-term swimming and fundraising commitment. Lizzie first joined CanToo's Summer Ocean Swim program back in 2009 with little knowledge of the ocean. She recalls being unable to recognise surf conditions or identify a rip, and she describes early sessions as a mix of fascination and fear. One memory captures those early challenges well: Annie Crawford, CanToo's Founder, sitting beside her after a difficult training session as she tried to regain her confidence.

This starting point - being new, unsure, and well supported - is familiar to many participants. It highlights a core impact of the CanToo model: people enter with varied skill levels but receive structured, steady guidance that helps them move from apprehension to capability.

20

Discovering strength and expanding possibility

What began as a single program grew into a long-term commitment. Over the years, Lizzie has completed more than 30 marathon swims, including major endurance events such as the Derwent River Big Swim (33.5km, solo), Palm to Shelly (27km, solo), and a relay crossing of the English Channel. Lizzie's fundraising is equally impressive, having raised over \$100,000 for CanToo.

These achievements show how CanToo programs can create a foundation that reshapes how participants understand their physical and emotional capacity. Lizzie explains her motivation simply: "We all have challenges in life, but we've forgotten that ordinary people are capable of extraordinary things."



Finding community during the hardest moments

The English Channel relay in 2019 became one of Lizzie's most meaningful experiences. Her team, the "Toocans," raised funds to support a 10km CanToo swim program, creating a ripple effect that enabled others to take on their own challenge.

The timing made the experience especially impactful. Lizzie's husband, who had planned to swim the Channel with the team, died unexpectedly that year. The training, companionship, and shared purpose provided a sense of stability and joy during a profoundly difficult period. "The things we achieved brought me immense happiness, solidarity and pride at a time when life was otherwise bereft of joy", Lizzie reflects.

A program that extends well beyond the finish line

For Lizzie, the most enduring impact has been the community itself. She describes friendships that span generations, inspiration drawn from people living with and managing cancer, and the confidence that comes from achieving something that once felt impossible.

Her advice to prospective participants is clear: “Anyone – young or old, whether you swim like a dolphin or a brick – just do it.”

Lizzie’s experience shows how a CanToo program can do more than teach a skill. It can widen a person’s sense of capability, strengthen resilience and connection, and create lasting pathways for personal and collective impact.



Our partners

CanToo would like to thank our partners, ASICS and Catfish, who make it possible for us to deliver on our dual mission through their incredible support.



Our running partner for apparel



Our ocean swim partner for apparel



For 20 years, our values have been to Inspire, Engage, Support, and Empower. Celebrating our 20th year, CanToo was thrilled to launch The Toucan Collective – a group of dedicated individuals who share these values, and have pledged their support to help us double our impact in the next five years. This means more programs, in more locations, so we can support more early-career cancer scientists with their groundbreaking research.

The Toucan Collective represent our closest supporters who pledge an annual investment through either philanthropic giving, program fundraising, or a combination, so that we can work to increase and expand our programs, ultimately empowering CanToo to raise more money for early-career cancer research.

- Co-funding eight early-career cancer researchers, backing bold ideas at a critical stage of their careers;
- Supporting the expansion of CanToo’s programs interstate, ensuring our long-term sustainability and growth as an organisation;
- Helping establish new training pods, enabling more people in Australia to access expert-led programs that support physical and mental wellbeing; and
- Raising over \$285k towards our dual mission.

“Simon and I are really proud and excited to be part of The Toucan Collective. Together, we can help every day people like you and me to face fears, move beyond our comfort zone and achieve physical and mental goals we may only have dreamed of. At the same time, we will fund research to change the face of cancer outcomes in this country. Together, we can help save the life of someone we love or even our own. Come on this journey with us. Go CanToo!!!”
- Annie Crawford, CanToo Founder

We are incredibly grateful to the inaugural members of The Toucan Collective, whose belief and generosity will ensure that CanToo can grow, innovate, and continue to deliver on our dual mission well into the future.

- Ben Buckingham
Jeffrey and Susan Cohn
Annie Crawford and Simon Buckingham
The Gallagher Family Foundation
Six Esses
- Vicky Kvisle
Clare Maple-Brown and Brad Kean
Nick and Kylie Pagent
Unsworth Foundation
Barbara King



Barbara King
Chair, Non-Executive Director



Jeffrey Cohn
Board Director, Chair of Research Committee



Mark Dagworthy
Board Director, Chair of Audit & Risk Committee



Ben Buckingham
Board Director



Antoine Van Oijen, PHD
Board Director



Dominic Del Giudice
Board Director

We are also grateful for the service of our now retired Board Directors:
Andrea Tustin (left November 2024)
Sarv Girn (left November 2024)
Anke Timm (left November 2024)
Michelle Smyth (left September 2024)
Abs Osseiran (left September 2024)

Our team

25



The CanToo team pictured above with CanToo-er, Lizzie Crowhurst, celebrating Lizzie's \$100k fundraising efforts.

Lisa Hresc - Chief Executive Officer

Gavin Le Roux - Finance Manager

Kirk Zhao - Financial Accountant

Conchita Casteigt - Head of Marketing and Fundraising

Lucy Boon - Senior Philanthropy and Partnerships Manager

Kat Salmons - Community Engagement Manager

Addy Andrasova - Community Engagement Coordinator

Lara Bisley - Head of Operations, Program Delivery and Experience (left November 2025)

Stacie Smith - Associate Programs Manager

Melissa Clifford - Business Growth and Engagement Lead

Dani Knowles - Programs Coordinator


Trish Dwight - Research Program Manager




Financial summary

27

Income



Expenditure



FY24/25 saw a small decrease in revenues to \$1.67m. Similar to FY23/24, we have seen a decrease in participation and peer-to-peer fundraising this year which has been offset by an increase in non-participant sourced income from major gifts and corporate programs.

Expenses have decreased by \$244k compared to last year mainly due to a reduction in fundraising and marketing. This resulted in an operating profit of \$69k, which is an \$80k increase from last year (before research grants). 8 cancer researchers have been supported in 2025.

Can Too Foundation is debt free and maintains sufficient working capital by managing the timing of cancer research funding. Can Too Foundation holds a diversified investment portfolio with JBWere, in accordance with a Board-approved investment policy, which provides interest income and is retained as a contingency and risk mitigant, particularly while the updated strategy is being implemented.

The financial accounts are overseen by a dedicated volunteer Board, with extra scrutiny being given by the Board’s Audit & Risk Committee. CanToo has independent, external auditors and we thank Prosperity for their services this year.

28

Statement of financial position as of 30 June

Assets	2025	2024
Cash and equivalents	\$245,070	\$112,329
Investments	\$1,081,926	\$1,395,456
Receivables	\$87,240	\$62,847
Inventory	\$40,172	\$38,438
Lease	\$345,137	\$37,280
Other	\$10,652	\$16,152
Total assets	\$1,810,198	\$1,662,501
Liabilities		
Provision for cancer research	\$50,954	\$155,492
Lease	\$346,192	\$43,738
Provisions for employee benefits	\$43,391	\$88,309
Payables	\$155,192	\$78,565
Total liabilities	\$595,729	\$366,104
Accumulated surplus	\$1,214,469	\$1,296,397

Statement of income and expenditure for the year ended

Income	2025	2024
Participant source donations	\$892,787	\$1,003,034
Donations from non-participant sources	\$365,080	\$325,643
Joining fees	\$208,312	\$170,542
Other income	\$199,684	\$229,714
Total income	\$1,665,863	\$1,728,933
Expenditure		
Cancer research	\$184,428	\$293,200
Health promotion salaries	\$438,612	\$462,048
Other health promotion	\$295,722	\$365,032
Administration salaries	\$255,564	\$292,085
Other administration	\$222,007	\$161,808
Fundraising salaries	\$229,947	\$174,054
Other fundraising	\$121,511	\$243,412
Total expenditure	\$1,747,791	\$1,991,639

Contact us

Connect with us

Visit cantoo.org.au for more information about our work, and to see how you can get involved.

Follow us on socials to hear all the latest news and stories @cantoorunswim



Email

info@cantoo.org.au

Phone

+61 477 018 660

Registered office & postal address

Suite 803, 1 Elizabeth Plaza, North Sydney
NSW 2060

Registered charity

Can Too Foundation Limited is a registered charity.

ABN: 53169310696



Join us

To take part in a CanToo program, please visit cantoo.org.au/participate to view all current available programs.

To support our work with a donation, please visit cantoo.org.au/donate-foundation

Thank you.

